Tagged News
Bispecific Antibodies: Promising Advances Amid Adoption Challenges in Cancer Treatment
• Bispecific antibodies represent a significant advancement in cancer immunotherapy, targeting both tumor antigens and immune cells to enhance cytotoxicity without requiring patient-derived cells like CAR-T therapy.
• Despite clinical promise with nine FDA-approved bispecific antibodies, adoption faces challenges including transition between inpatient/outpatient settings, insurance coverage, adverse event management, and financial barriers in community settings.
• Recent approvals of Mosunetuzumab, Glofitamab, and Epcoritamab have shown impressive response rates in relapsed/refractory indolent B-cell lymphomas, with manageable toxicity profiles when using step-up dosing strategies.
Related Clinical Trials:
Reid Merryman, MD
Posted 7/18/2023
NCT05529524Completed
The Lymphoma Academic Research Organisation
Posted 11/7/2022
The Lymphoma Academic Research Organisation
Posted 9/5/2023
Abramson Cancer Center at Penn Medicine
Posted 11/5/2021
Genmab
Posted 11/3/2020
Weill Medical College of Cornell University
Posted 11/1/2023
University of Washington
Posted 3/23/2022
Hoffmann-La Roche
Posted 10/27/2021
Novel Targets and Strategic Sequencing: The Evolving Landscape of T-Cell Redirection Therapies in Multiple Myeloma
• CAR T-cell therapies and bispecific antibodies targeting BCMA and GPRC5D are transforming multiple myeloma treatment, with ciltacabtagene autoleucel showing unprecedented efficacy with a median PFS of 34.9 months in heavily pretreated patients.
• Disease progression rate is a critical factor in therapy selection, with rapidly progressing patients better suited for "off-the-shelf" bispecific antibodies, while patients with indolent disease may benefit more from CAR T-cell therapies despite longer manufacturing times.
• Strategic sequencing of therapies is crucial, as prior BCMA-directed bispecific antibody treatment significantly reduces the efficacy of subsequent BCMA-targeted CAR T-cell therapy, highlighting the importance of preserving T-cell fitness and considering antigen loss.
Related Clinical Trials:
Celgene
Posted 4/16/2019
Janssen Research & Development, LLC
Posted 9/17/2020
Janssen Research & Development, LLC
Posted 2/1/2021
Janssen Research & Development, LLC
Posted 6/29/2018
Pfizer
Posted 2/2/2021
Janssen Research & Development, LLC
Posted 6/12/2020
Celgene
Posted 12/18/2017
Janssen Research & Development, LLC
Posted 11/7/2019
Novartis's Kymriah: Breakthrough CAR-T Therapy Priced at $475,000 Sparks Value Debate
• Novartis's Kymriah, the first FDA-approved CAR-T cell therapy for pediatric acute lymphoblastic leukemia, demonstrates an impressive 83% remission rate in patients who failed traditional treatments.
• The therapy's $475,000 price tag has ignited debate among healthcare experts, with some defending it as comparable to bone marrow transplants while others argue it's excessive despite its breakthrough status.
• Novartis has implemented innovative value-based pricing models, including outcome-based contracts where payment is contingent upon patient response and indication-specific pricing for future approvals.